However, the agency noted officials cannot rule out that 'a small risk may exist,' and it will continue to investigate
Functioning and mental health benefits sustained at one-month follow-up
Strongest demographic predictor for discharge initiation of medications for alcohol use disorder was younger age
No increased risk for suicidal ideation seen with semaglutide versus non-GLP1R agonist antiobesity medications
FDA is investigating reports of hair loss, aspiration, and suicidal thoughts among people taking the medications
Dulaglutide effective in preventing substantial weight gain, which was more common in women
Autism, substance-related disorders, disruptive disorders were diagnoses with highest rates of pharmacologic restraint days
Higher doses of prescription psychostimulants, treatment duration positively linked to longer retention
4 percent increase in risk for CVD seen in association with each one-year increase in ADHD meds across 14 years of follow-up
One of five trials in the FDA review was positive; all three trials in the published literature were positive